BICYCLE THERAPEUTICS PLC

Sell‑to‑cover trades at Bicycle Therapeutics reveal routine tax‑planning, not a signal of weakness—insiders remain confident while the stock steadies near $3.79.

Investor insight: Bicycle Therapeutics’ COO sales are routine tax‑cover moves, not a confidence drop—understand the risk‑reward before buying.

Insider sell‑to‑cover moves at Bicycle Therapeutics are routine tax‑cover sales, priced near market and unlikely to signal a shift in company confidence or liquidity.

Insider sell‑to‑cover actions at Bicycle Therapeutics show routine tax‑cover activity, not ownership shifts—key for investors watching the company’s stock and RSU program.

Insider holdings at Bicycle Therapeutics reveal steady, long‑term confidence from senior managers, offering investors a reassuring signal amid volatile stock performance.

Travis Thompson’s 58,000‑share option buy at Bicycle Therapeutics signals long‑term confidence despite recent sales—an insider move worth watching for future upside.

COO Milnes Alistair’s January 2026 RSU award and option purchase signal strategic confidence in Bicycle Therapeutics’ future, hinting at potential upside despite current market volatility.